FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Rare Pediatric Disease Status for Leukemia Drug

[ Price : $8.95]

FDA gives Sellas Life Sciences Group a Rare Pediatric Disease Designation for SLS009, a highly selective CDK9 inhibitor for treati...

Priority Voucher Used for Vyvgart Hytrulo sNDA

[ Price : $8.95]

Federal Register notice: FDA announces that Argenxs supplemental NDA for Vyvgart Hytrulo for treating chronic inflammatory demyeli...

GMP Violations in YangZhou Records Review

[ Price : $8.95]

FDA warns Chinas YangZhou SuXiang Medical Instrument Co. about CGMP violations in its manufacturing of finished drugs.

CGMP Violations at Jiangsu Hengrui

[ Price : $8.95]

FDA warns Chinas Jiangsu Hengrui Pharmaceuticals about CGMP violations in its manufacturing of finished drugs

Combination Product Application User Fees

[ Price : $8.95]

FDA publishes a guidance on how it calculates combination product application user fees.

FDA Accepts Lexicon NDA for Resubmitted Diabetes Drug

[ Price : $8.95]

FDA accepts for review a resubmitted Lexicon Pharmaceuticals NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy fo...

Guidance on Pediatric IBD Drug Development

[ Price : $8.95]

FDA publishes a draft guidance for sponsors working to develop drugs to treat pediatric inflammatory bowel disease.

FDA Wants to Stem Common Chronic Diseases: Califf

[ Price : $8.95]

FDA commissioner Robert Califf says many stakeholders need to work together to improve interventions for common chronic diseases.

Smith+Nephew New Hip System Cleared

[ Price : $8.95]

FDA clears a Smith+Nephew 510(k) for its new Catalystem Primary Hip System.

Issues in MIT Institutional Review Board

[ Price : $8.95]

FDA warns the MIT IRB on using humans as experimental subjects about repeat violations of regulations.